Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Regulation FD Disclosure

Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

On January7, 2019,Idera Pharmaceuticals,Inc. (the “Company”) uploaded a presentation to its website, www.iderapharma.com, discussing the state of the Company. We may rely on all or part of this presentation any time we are discussing the current state of the Company in communications with investors or at conferences. A copy of the presentation is attached to this Current Report on Form8-K as Exhibit99.1 (the “Presentation”).

The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (the “SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The Company is furnishing the information in this Item 7.01 and the related Exhibit99.1 filed herewith to comply with Regulation FD. Such information shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing. This Item 7.01 will not be deemed an admission as to the materiality of any information herein (including Exhibit99.1) that is required to be disclosed solely by Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

See the ExhibitIndex below, which is incorporated by reference herein.

ExhibitIndex

ExhibitNo.

ExhibitName

99.1

Investor Presentation dated January7, 2019.

IDERA PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a19-1337_1ex99d1.htm EX-99.1 Exhibit 99.1 Idera Pharmaceuticals 37th Annual J.P. Morgan Healthcare Conference January 2019   This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,…
To view the full exhibit click here

About Idera Pharmaceuticals,Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

An ad to help with our costs